KALV(Delisted)
Stock Fundamental
Valuation2.0/10
BearishKey Valuation Metric
PE Method: KALV's market cap is approximately 1.44B with TTM earnings of -42.75B, corresponding to a PE ratio of -3.4. Compared to the Pharmaceuticals industry average, this valuation may be undervalued.
PEG Method: With a PE of -3.4 and forward PE of -3.4, the PEG ratio comes to 0.99, indicating a reasonable valuation.
Historical Price to Earnings Ratio
Historical data shows that KALV's P/E reached a peak of about -2.34 on 2025-01-14, and a trough of about -6.04 on 2024-02-27. The current P/E is -3.36, which places it at approximately the 72% percentile of its historical range, indicating a relatively reasonable valuation.
Share Price vs Future Cash Flow Value
KALV's current stock price is about $27.00, while its Discounted Cash Flow valuation is about $29.46. Based on the Discounted Cash Flow model, the market price represents a price close to its intrinsic value.
Future Growth6.4/10
NeutralEarnings and Revenue Growth Forecasts
KALV's Revenue moved from about 13.69M (2025) to about 40.86M (2026) in recent actuals. Analyst forecasts include about 31.81M, 31.81M, and 31.81M for the next forecast periods, implying an overall 3-year CAGR of roughly -8.0% versus the latest actual—indicating a downward trend in Revenue..
Future Return on Equity
Analysts predict KALV's future return on equity (Future ROE) will be about -105.7% over the next three years, lower than the Pharmaceuticals industry average of -48.3%, indicating its backward position in capital profitability. A higher Future ROE generally reflects stronger expected profitability on shareholder equity, subject to business risk and accounting differences.
Past Performance7.7/10
BullishRevenue & Expenses Breakdown
Earnings & Revenue
- Earnings per share (TTM)-3.13
- Gross margin58.63%
- Net profit margin-4214.31%
- Debt / equity-17.74x
The company's earnings quality is weaker. Net profit for the latest fiscal period is about -60.10M, while free cash flow is estimated at -27.47M. The 32.63M difference between the two indicates significant cash conversion capabilities. suggesting a meaningful gap between accounting earnings and cash generation, often driven by non-cash items or working capital.
Free Cash Flow vs Earnings Analysis
KALV's net income is about -26.11M, while free cash flow is about -27.47M, representing a FCF/Earnings ratio of 105.2%. The conversion from earnings to free cash flow is efficient, indicating strong cash generation relative to book earnings.
Financial Health5.5/10
NeutralDebt to Equity History and Analysis
In 2026-03, total liabilities (Debt) are about 348.57M; total equity (Equity) is about -19.65M. These figures come from the financial health diagnose series (debt / equity). They describe capital structure, not operating earnings.
Balance Sheet
Assets
Liabilities + Equity
Dividends4.0/10
NeutralStability and Growth of Payments
KALV is not paying a notable dividend in the U.S. market context; detailed stability and growth checks are less relevant until distributions become material.
Dividend Yield vs Market
KALV's current dividend yield is 0.00%, while the Pharmaceuticals industry average is around 3.56%. The top 25% of companies in the entire US market have a dividend yield of 4.56%, while the bottom 25% have a yield of 2.48%. In comparison, KALV is clearly at the bottom of the industry.
Earnings Payout to Shareholders
Earnings coverage: KALV is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash flow coverage: KALV is not paying a notable dividend for the US market.
- Based on a composite score of 5.97/10, we rate KALV as a Netural. Our analysis breaks down into 6.09/10 for Fundamentals, 6.35/10 for Technicals, and 6.87/10 for Sentiment, indicating the stock is likely to consolidate sideways.
- Based on a composite score of 5.97/10, we rate KALV as a Netural. Our analysis breaks down into 6.09/10 for Fundamentals, 6.35/10 for Technicals, and 6.87/10 for Sentiment, indicating the stock is likely to consolidate sideways.
